Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14230838 | 0.87 | GPR119 (0.46) | GPR119ALOX5APFEN1FAAHCNR2 | |
| SCHEMBL25019245 | 0.85 | FFAR4 (0.45) | CNR2 | |
| SCHEMBL25113635 | 0.85 | GPR119 (0.49) | GPR119 | |
| SCHEMBL25677249 | 0.85 | CNR2 (0.38) | GPR119ALOX5APFEN1CNR2 | |
| SCHEMBL14239622 | 0.84 | GPR119 (0.48) | GPR119ALOX5APFEN1FAAHSCN9A | |
| SCHEMBL457651 | 0.82 | GPR119 (0.56) | GPR119FAAHCHEK2 | |
| SCHEMBL14230926 | 0.81 | ALOX5AP (0.45) | GPR119ALOX5APFEN1FAAHCNR2 | |
| SCHEMBL14230928 | 0.81 | ALOX5AP (0.45) | GPR119ALOX5APFEN1FAAHCNR2 | |
| SCHEMBL19461969 | 0.79 | FAAH (0.50) | GPR119FAAHCHEK2 | |
| SCHEMBL1103942 | 0.79 | GPR119 (0.57) | GPR119ALOX5APFEN1FAAHCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2008038011-A1 | PYRIMIDINE DERIVATIVES AS AURORA A AND AURORA B INHIBITORS | VERNALIS (R & D) LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038011-A1 | PYRIMIDINE DERIVATIVES AS AURORA A AND AURORA B INHIBITORS | VERNALIS (R & D) LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | GPR119 769/4885ALOX5AP 4577/4885FEN1 3253/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | GPR119 769/4885ALOX5AP 4577/4885FEN1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.